Loading clinical trials...
Loading clinical trials...
The current study is a phase II multi-center single arm trial to evaluate the efficacy and safety of adding Anti-PD-1 antibody in an inductive and concurrent way to radiotherapy in early-stage low-ris...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Chinese Academy of Medical Sciences
Collaborators
NCT07527741 · Early-stage HER2+ Breast Cancer
NCT06970912 · Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, and more
NCT05559164 · Cardiac Toxicity, Early-stage Breast Cancer
NCT04553770 · Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, and more
NCT05760612 · Early-stage Breast Cancer, HER2-positive Breast Cancer, and more
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions